A carregar...

Global Proteome Quantification for Discovering Imatinib-induced Perturbation of Multiple Biological Pathways in K562 Human Chronic Myeloid Leukemia Cells

Imatinib mesylate, currently marketed by Novartis as Gleevec in the US, has emerged as the leading compound to treat chronic phase of chronic myeloid leukemia (CML), through its inhibition of Bcr-Abl tyrosine kinase, and other cancers. However, resistance to imatinib develops frequently, particularl...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Xiong, Lei, Zhang, Jing, Yuan, Bifeng, Dong, Xiaoli, Jiang, Xinning, Wang, Yinsheng
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2974763/
https://ncbi.nlm.nih.gov/pubmed/20949922
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/pr100814y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!